SIRT6 restrains hyperactivated Nrf2 to enhance cisplatin response in lung cancer models
Biochemical and Biophysical Research Communications · 2026-10 · 836 · 154563
DOI: 10.1016/j.bbrc.2026.154563 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2026-10. Verfasst von Zhengpan Xiao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Tropical Biological Resources of the Ministry of Education of China, School of Pharmaceutical Sciences, Hainan University, Haikou, …. Hauptthemen laut MEDLINE: Cisplatin, NF-E2-Related Factor 2, Lung Neoplasms, Sirtuins. Die Arbeit nennt 16 Literaturangaben. Gefördert von: Natural Science Foundation of Hainan Province, Hainan Provincial Department of Science and Technology, National Natural Science Foundation of China.
Abstract (Originalsprache)
Persistent Nrf2 activation promotes tumor adaptation and chemoresistance, but mechanisms that restrain excessive Nrf2 signaling remain unclear. We investigated whether SIRT6 regulates Nrf2 in a state-dependent manner and influences cisplatin response using clinical database analyses, genetic and pharmacological interventions, A549 and HCC827 cells, and an A549 xenograft model. High NFE2L2 expression and a low-SIRT6/high-NFE2L2 pattern were associated with unfavorable outcomes. Nrf2 overexpression or tBHQ activation reduced cisplatin sensitivity, whereas SIRT6 overexpression, MDL-800 treatment, or Nrf2 inhibition enhanced cisplatin response. In xenografts, MDL-800 enhanced cisplatin-induced tumor suppression and partially reversed the protective effect of tBHQ. SIRT6 modestly increased basal ARE activity but suppressed transcription activated by Nrf2 overexpression, tBHQ, or CBP. This suppression persisted after proteasome or ubiquitination-pathway inhibition and was accompanied by reduced Nrf2 acetyl-lysine signal and nuclear accumulation. G60A retained inhibitory activity, whereas R65A showed markedly reduced inhibition; however, their context-dependent catalytic properties preclude assignment of a specific enzymatic mechanism and do not establish direct Nrf2 deacetylation. Mutational analysis functionally implicated the K599/K603/K604 cluster in SIRT6-sensitive regulation. Together, these findings identify a state-dependent SIRT6-Nrf2 relationship and suggest that SIRT6 restrains excessive Nrf2 activity through an acetylation-linked mechanism, thereby enhancing cisplatin response in lung cancer models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Tropical Biological Resources of the Ministry of Education of China, School of Pharmaceutical Sciences, Hainan University, Haikou, 570228, China; Laboratory of Biopharmaceuticals and Molecular Pharmaco…
- Laboratory of Biopharmaceuticals and Molecular Pharmacology, One Health Cooperative Innovation Center, Hainan University, Haikou, 570228, China; Department of Biotechnology, School of Life and Health, Hainan University,…
Förderung
- Natural Science Foundation of Hainan Province
- Hainan Provincial Department of Science and Technology
- National Natural Science Foundation of China
Zitieren
APA
Xiao, Z., Fu, W., Wei, S., Pei, Y., Min, Y., & Wang, D. (2026). SIRT6 restrains hyperactivated Nrf2 to enhance cisplatin response in lung cancer models. Biochemical and Biophysical Research Communications, 836, 154563. https://doi.org/10.1016/j.bbrc.2026.154563
Vancouver
Xiao Z, Fu W, Wei S, Pei Y, Min Y, Wang D. SIRT6 restrains hyperactivated Nrf2 to enhance cisplatin response in lung cancer models. Biochemical and Biophysical Research Communications. 2026;836:154563. doi:10.1016/j.bbrc.2026.154563
BibTeX
@article{Xiao2026,
author = {Xiao, Zhengpan and Fu, Wanmeng and Wei, Shuangshuang and Pei, Yechun and Min, Yi and Wang, Dayong},
title = {SIRT6 restrains hyperactivated Nrf2 to enhance cisplatin response in lung cancer models},
journal = {Biochemical and Biophysical Research Communications},
year = {2026},
volume = {836},
pages = {154563},
doi = {10.1016/j.bbrc.2026.154563}
}
EUVIMED